+Vote!
Business Wire (Free subscription) | yesterday
DETROIT--(BUSINESS WIRE)--Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years. The agreement...
4Vote!
Business Wire (Free subscription) | 11/16/2009
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver value to Bristol-Myers Squibb shareholders. The split-off is expected to be net cash flow positive to the BioPharma business and accretive...
5Vote!
Business Wire (Free subscription) | 11/16/2009
GLENVIEW, Ill.--(BUSINESS WIRE)--Mead Johnson Nutrition Company (NYSE: MJN) announced today that it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC), which includes details of a proposed exchange offer whereby Bristol-Myers Squibb Company (BMS) shareholders can exchange some, none or all of their shares of BMS common stock for...
4Vote!
Business Wire (Free subscription) | 11/10/2009
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a Credit Suisse healthcare conference on Thursday, November 12, 2009 in Phoenix, Arizona. Jean-Marc Huet, executive vice president and chief financial officer of Bristol-Myers Squibb, will make a formal presentation about the company at 10:30 a.m. ET. Investors and the general public are invited...
4Vote!
Business Wire (Free subscription) | 11/10/2009
PRINCETON, N.J. & BOTHELL, Wash.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. Under the terms of the collaboration agreement, Alder will grant to...
4Vote!
Business Wire (Free subscription) | 11/02/2009
ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing...
3Vote!
Medical News Today (Free subscription) | 11/03/2009
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested.
4Vote!
Business Wire (Free subscription) | 10/31/2009
PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was...
4Vote!
Business Wire (Free subscription) | 10/29/2009
PENNINGTON, N.J.--(BUSINESS WIRE)--Students at The Pennington School will have an unprecedented opportunity this year to conduct hands-on, high-tech science projects, thanks to sophisticated science equipment donated by Bristol-Myers Squibb Company (NYSE: BMY). The instrument – an atomic absorption spectrometer – measures the amounts of different chemical elements present...
4Vote!
Business Wire (Free subscription) | 10/27/2009
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study). The first patient has been dosed in the study, triggering a $70 million milestone payment to ZymoGenetics from ...
3Vote!
Medical News Today (Free subscription) | 10/29/2009
Liver Disease / Hepatitis NewsZymoGenetics Initiates Phase 2 Clinical Trial Of PEG-Interferon Lambda In Hepatitis C With Bristol-Myers SquibbZymoGenetics, Inc. (NASDAQ: ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic C virus (HCV) infection (the "EMERGE" study). The first patient has been dosed...
3Vote!
Medical News Today (Free subscription) | 10/26/2009
Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
4Vote!
Business Wire (Free subscription) | 10/24/2009
SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data from study XL184-201 were presented today during a poster...
+Vote!
Business Wire (Free subscription) | 10/22/2009
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported strong sales and earnings growth for the third quarter 2009. “The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution,” said James M. Cornelius, chairman and chief executive...
